CRP and cancer: These findings, if verified in further studies, puts CRP in a new perspective, acting not only as a biomarker of unfavorable prognosis and outcomes in cancer, but also as an active mediator with direct effects within tumors, and opens a new and intriguing approach for targeting the TME.